Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:26:02.892Z.
Calculation as of: 2026-10-06T16:26:02.892Z.
Quote observation: 2026-10-06T16:25:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756
PE RATIO
N/A
Market Cap
$718.52M
PE Ratio
N/A
TTM Avg
991.02
3Y Avg
502.52
5Y Avg
502.52
Market Cap
$715.81M
PE Ratio
17.80
TTM Avg
23.33
3Y Avg
39.10
5Y Avg
32.90
Market Cap
$712.26M
PE Ratio
N/A
TTM Avg
359.25
3Y Avg
359.25
5Y Avg
359.25
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $738.93M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $737.40M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $718.52M | N/A | 991.02 | 502.52 | 502.52 |
| Design Therapeutics, Inc. (DSGN)vs › | $760.10M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.81M | 17.80 | 23.33 | 39.10 | 32.90 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $712.26M | N/A | 359.25 | 359.25 | 359.25 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $709.26M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $705.61M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $769.94M | 163.80 | 129.79 | 309.15 | 358.87 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.09
Forward EPS (Est.)
$-1.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
